Ginkgo Bioworks Holdings (DNA) AI Stock Analysis

• Market Cap: $551.98M
• Dividend Yield: N/A
• Average Volume (3M): 1.26M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.84
• Revenue Growth: -17.13%
• EPS Growth: 51.74%
• Country: US
• Employees: 834
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.45
• Shares Outstanding: 48,523,594
• 10 Day Avg. Volume: 1,118,233
• 30 Day Avg. Volume: 1,262,173
• PEG Ratio: 0.02
• Price to Book (P/B): 0.71
• Price to Sales (P/S): 2.24
• P/FCF Ratio: -1.33
• Enterprise Value/Market Cap: 1.38
• Enterprise Value/Revenue: 4.23
• Enterprise Value/Gross Profit: 5.81
• Enterprise Value/Ebitda: -2.35
• 1Y Price Target: $14.00
• Price Target Upside: 74.35% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 3
• EPS Forecast (FY): -5.25
• Revenue Forecast (FY): $177.07M

• Rating: 40 Underperform
• Price Target: $8.50 ▲(5.85% Upside)

Ginkgo Bioworks Holdings faces significant financial challenges with declining revenues and substantial losses, which are the most impactful factors in the overall score. Technical indicators also suggest a bearish outlook, and the negative P/E ratio reflects ongoing profitability issues. While strategic expansions and cost reductions are positive, they are insufficient to outweigh the current financial and technical weaknesses.

Positive Factors

Cash Position

A strong cash position with no bank debt provides financial flexibility and stability, allowing Ginkgo to invest in growth initiatives and weather economic uncertainties.

Strategic Partnerships

Long-term partnerships with major companies like Bayer enhance Ginkgo's market position and revenue potential, supporting sustainable business growth through collaborative innovation.

AI and Automation Initiatives

Investing in AI and automation positions Ginkgo for future efficiency gains and revenue diversification, aligning with industry trends towards digital transformation.

Negative Factors

Revenue Decline

Significant revenue decline in key segments like Cell Engineering indicates challenges in maintaining growth, which can impact long-term financial health and market competitiveness.

Operating Losses

Rising operating losses in core segments suggest operational inefficiencies and cost management issues, potentially affecting profitability and strategic execution.

Negative Cash Flows

Persistent negative cash flows limit the company's ability to fund operations and growth internally, increasing reliance on external financing and impacting long-term viability.

Ginkgo Bioworks Holdings Business Overview & Revenue Model

Company Description

Ginkgo Bioworks Holdings, Inc. is a biotechnology company that specializes in organism engineering. Founded in 2008 and headquartered in Boston, Massachusetts, Ginkgo operates in various sectors, including pharmaceuticals, agriculture, and food production. The company leverages its proprietary platform to design custom microbes for a range of applications, from producing ingredients for consumer products to optimizing agricultural outputs. Ginkgo's core services include strain development, fermentation, and bio-manufacturing, aimed at creating more sustainable and efficient solutions in biotechnology.

How the Company Makes Money

Ginkgo Bioworks generates revenue through several key streams primarily focused on its partnerships and customer contracts in the biotechnology sector. The company collaborates with various organizations, including pharmaceutical, agricultural, and industrial companies, to develop custom organisms tailored to specific needs. Revenue is generated from service fees for its organism design and development services, as well as from licensing agreements that allow partners to utilize Ginkgo's proprietary technologies. Additionally, Ginkgo may earn royalties from commercialized products developed using its engineered organisms. Significant partnerships with major corporations enhance Ginkgo’s revenue potential by providing access to larger markets and more substantial projects, contributing notably to its earnings.

Ginkgo Bioworks Holdings Financial Statement Overview

Summary

Ginkgo Bioworks Holdings is facing significant financial challenges with declining revenues, substantial losses, and negative cash flows. Despite a reasonable debt-to-equity ratio, persistent negative profitability and cash flow issues pose risks to financial stability.

Income Statement

Ginkgo Bioworks Holdings has experienced declining revenue over the TTM period with a significant negative revenue growth rate of -21.75%. The company shows strong gross profit margins, but the net profit margin is deeply negative, indicating substantial losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high costs relative to revenue.

Balance Sheet

The company's debt-to-equity ratio has increased over time, indicating rising leverage, but remains moderate at 0.76. Return on equity is negative, reflecting ongoing losses. The equity ratio is relatively stable, suggesting a reasonable proportion of equity financing, but the overall financial health is weakened by persistent losses.

Cash Flow

Ginkgo Bioworks Holdings has negative operating and free cash flows, with a declining free cash flow growth rate of -31.73% in the TTM period. The operating cash flow to net income ratio is negative, indicating cash flow challenges. However, the free cash flow to net income ratio is positive, suggesting some ability to cover net losses with free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	180.61M	227.04M	251.46M	477.71M	313.84M	76.66M
Gross Profit	131.31M	188.49M	197.45M	273.49M	184.15M	61.05M
EBITDA	-324.47M	-484.39M	-821.29M	-2.06B	-1.81B	-108.58M
Net Income	-339.55M	-547.03M	-892.87M	-2.10B	-1.83B	-126.61M
Balance Sheet
Total Assets	1.19B	1.38B	1.67B	2.54B	2.07B	675.15M
Cash, Cash Equivalents and Short-Term Investments	461.86M	561.57M	944.07M	1.32B	1.55B	380.80M
Total Debt	422.87M	467.73M	239.31M	442.59M	23.03M	17.00M
Total Liabilities	629.38M	661.39M	568.19M	803.04M	503.61M	205.10M
Stockholders Equity	559.78M	716.06M	1.10B	1.74B	1.51B	461.38M
Cash Flow
Free Cash Flow	-187.19M	-382.13M	-336.30M	-304.47M	-310.34M	-193.65M
Operating Cash Flow	-165.82M	-319.58M	-295.50M	-252.20M	-253.82M	-135.83M
Investing Cash Flow	-348.47M	-62.24M	-80.69M	-67.39M	-73.26M	-67.12M
Financing Cash Flow	9.43M	-1.74M	-3.22M	95.34M	1.53B	90.32M

Ginkgo Bioworks Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNA, the sentiment is Negative. The current price of 8.03 is below the 20-day moving average (MA) of 9.44, below the 50-day MA of 11.91, and below the 200-day MA of 10.09, indicating a bearish trend. The MACD of -1.09 indicates Negative momentum. The RSI at 42.25 is Neutral, neither overbought nor oversold. The STOCH value of 89.41 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DNA.

Ginkgo Bioworks Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MAZE	59 Neutral	$1.83B	―	-36.13%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TRML	45 Neutral	―	―	-29.62%	―	―	6.66%
RAPP	44 Neutral	$1.40B	―	-23.41%	―	―	―
DNA	40 Underperform	$551.98M	―	-50.02%	―	-17.13%	51.74%
ERAS	34 Underperform	$888.02M	―	-32.00%	―	―	45.66%
SANA	33 Underperform	$1.07B	―	-96.11%	―	―	31.16%

Ginkgo Bioworks Holdings Corporate Events

Ginkgo Bioworks Earnings Call: Mixed Sentiments and Strategic Moves

Ginkgo Bioworks Holdings, Inc. recently held its earnings call, revealing a mixed sentiment among stakeholders. While the company celebrated significant achievements in cost reductions and strategic partnerships, challenges such as revenue declines and increased operating losses in the Cell Engineering segment painted a complex picture of its financial health. Despite these hurdles, Ginkgo’s strategic maneuvers indicate a forward-looking approach aimed at future growth.

Ginkgo Bioworks Reports Q3 2025 Financial Results

Ginkgo Bioworks Holdings, Inc. is a biotechnology company specializing in the development of tools and technologies to make biology easier to engineer, focusing on sectors such as therapeutics, diagnostics, and manufacturing. The company also offers biosecurity solutions to address biological threats.

Ginkgo Bioworks Enters Sales Agreement for Stock Offering

On September 4, 2025, Ginkgo Bioworks Holdings entered into a Sales Agreement with Allen & Company LLC to potentially sell up to $100 million of its Class A common stock in at-the-market offerings. The proceeds from these sales, if any, are intended for general corporate purposes, including financing operations and technology development. The agreement allows flexibility in selling shares and includes customary rights and termination options for both parties. This move could impact the company’s market positioning by providing additional capital to support its growth and operations in the competitive synthetic biology industry.

The most recent analyst rating on (DNA) stock is a Sell with a $9.00 price target. To see the full list of analyst forecasts on Ginkgo Bioworks Holdings stock, see the DNA Stock Forecast page.

Ginkgo Bioworks Settles Stockholder Derivative Actions

On May 27, 2025, Ginkgo Bioworks Holdings reached a Stipulation and Agreement of Settlement to resolve stockholder derivative actions against certain individuals. The settlement, preliminarily approved by the court on August 21, 2025, includes a $4,125,000 insurance-funded payment, corporate governance reforms, and the dismissal of the actions. A final hearing is set for December 18, 2025.

The most recent analyst rating on (DNA) stock is a Sell with a $9.00 price target. To see the full list of analyst forecasts on Ginkgo Bioworks Holdings stock, see the DNA Stock Forecast page.